🇺🇸 FDA
Patent

US 11660352

Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof

granted A61KA61K47/6811A61K47/6849

Quick answer

US patent 11660352 (Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof) held by The Board of Regents of the University of Texas System expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K47/6811, A61K47/6849, A61K47/6851, A61K47/6879